<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02936492</url>
  </required_header>
  <id_info>
    <org_study_id>17014</org_study_id>
    <nct_id>NCT02936492</nct_id>
  </id_info>
  <brief_title>BAY1003803 Single and Multiple Dose Escalation, Safety, Tolerability and Pharmacokinetics Study</brief_title>
  <official_title>Escalating Dose Study for Safety, Tolerability and Pharmacokinetics After Single and Multiple Dermal Administration of Two BAY1003803 Formulation Types With Two Concentrations Each in Healthy Male Volunteers, Applying a Double-blind, Vehicle-controlled Design and Including a Positive Control Group</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Systemic safety following single and multiple dermal administration of BAY1003803
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">October 24, 2016</start_date>
  <completion_date type="Actual">October 16, 2017</completion_date>
  <primary_completion_date type="Actual">April 18, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cortisol serum levels for safety</measure>
    <time_frame>Up to 2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Nature of treatment-emergent adverse events (TEAEs)</measure>
    <time_frame>Up to 2 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Monocytic human leukocyte antigen-DR (HLA-DR) expression (Part 1, single dose)</measure>
    <time_frame>Day 1 to 3 at 8:00 am</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monocytic human leukocyte antigen-DR (HLA-DR) expression (Part 2, multiple dose)</measure>
    <time_frame>Day 1 to 8 at 8:00 am</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax) after single dose of BAY1003803</measure>
    <time_frame>At pre-dose, 1.5, 3, 5, 7, 9, 11, 13, 15, 21, 22, 23, 24 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration vs. time curve from zero to infinity (AUC) after single dose of BAY1003803</measure>
    <time_frame>At pre-dose, 1.5, 3, 5, 7, 9, 11, 13, 15, 21, 22, 23, 24, 27, 31, 35, 39, 47 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time zero to 22 hours [AUC(0-22)] after single dose of BAY1003803</measure>
    <time_frame>At pre-dose, 1.5, 3, 5, 7, 9, 11, 13, 15, 21, 22 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration (Cmax,md) after multiple dose of BAY1003803</measure>
    <time_frame>At pre-dose, 3, 7, 9, 11, 13, 22, 23 hours (Day 1); At pre-dose, 3, 7, 9, 11, 13, 22, 23, 24 hours (Day 2 and Day 6)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve from time zero to 24 hours [AUC(0-24)md] after multiple dose of BAY1003803</measure>
    <time_frame>At pre-dose, 3, 7, 9, 11, 13, 22, 23 hours (Day 1); At pre-dose, 3, 7, 9, 11, 13, 22, 23, 24 hours (Day 2 and Day 6)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>BAY1003803</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Topical treatment: dose escalating in 9 steps from 0.13 mg to 61.7 mg per subject</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Topical treatment using matching amount of placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clobetasol propionate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Topical treatment using 16.5 mg of clobetasol propionate per subject</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1003803 0.01% lipophilic cream</intervention_name>
    <description>Topical administration for 22 h per day</description>
    <arm_group_label>BAY1003803</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1003803 0.1% lipophilic cream</intervention_name>
    <description>Topical administration for 22 h per day</description>
    <arm_group_label>BAY1003803</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1003803 0.01% ointment</intervention_name>
    <description>Topical administration for 22 h per day</description>
    <arm_group_label>BAY1003803</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BAY1003803 0.1% ointment</intervention_name>
    <description>Topical administration for 22 h per day</description>
    <arm_group_label>BAY1003803</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lipophilic cream vehicle</intervention_name>
    <description>Topical administration for 22 h per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ointment vehicle</intervention_name>
    <description>Topical administration for 22 h per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clobetasol propionate</intervention_name>
    <description>Topical administration for 22 h per day</description>
    <arm_group_label>Clobetasol propionate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subject

          -  Age: 18 to 64 years (inclusive) at the first screening visit

          -  Body mass index (BMI): above or equal 18 and below or equal 30 kg / mÂ² at the first
             screening visit

          -  Non-smoker at least 3 months prior to study start and during the study

          -  Healthy skin on which reddening can be easily recognized

        Exclusion Criteria:

          -  A history of relevant diseases, especially incompletely cured pre-existing diseases
             for which it can be assumed that the absorption, distribution, excretion and effect of
             the study drugs will not be normal, dermal diseases, diseases which present a risk for
             subjects to be treated with glucocorticoid receptor agonists (e.g. gastric ulcers,
             cornea ulcer, colitis ulcerosa, severe infections, glaucoma, diabetes, myocardial
             infarction, thromboembolic disease, hypertension, thyroid disease, tuberculosis,
             myasthenia gravis, osteoporosis, psychiatric diseases)

          -  Infections and febrile illness within 4 week before the first study drug
             administration

          -  Use of systemic or topical medicines or substances which oppose the study objectives
             or which might influence them

          -  Inoculations with live vaccine within 8 weeks before the first study drug
             administration

          -  Signs of irritation or folliculitis or any other dermatological conditions in the test
             areas that would interfere with the planned assessments as judged by the Investigators

          -  Human leukocyte antigen-DR (HLA-DR) &lt; 15000 AB/monocyte
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Hamburg</city>
        <zip>20251</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 17, 2016</study_first_submitted>
  <study_first_submitted_qc>October 17, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <last_update_submitted>November 6, 2017</last_update_submitted>
  <last_update_submitted_qc>November 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase I</keyword>
  <keyword>Healthy volunteers</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clobetasol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

